

CAPSID-Studie: Eine randomisierte, prospektive, offene klinische Studie von Rekonvaleszentenplasma verglichen mit bestmöglicher supportiver Behandlung bei Patienten mit schwerem COVID-19

1. Mair-Jenkins J, Saavedra-Campos M, Baillie JK et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. *J.Infect.Dis.* 2015;211:80-90.
2. Shen C, Wang Z, Zhao F et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. *JAMA* 2020
3. Duan K, Liu B, Li C et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. *Proc.Natl.Acad.Sci U.S.A* 2020;117:9490-9496.